FDA Approves Amgen’s Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women with Osteoporosis
Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved Prolia(TM) (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Original Source of FDA Approves Amgen’s Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women with Osteoporosis
